文献速递生殖医学

基于卵裂期胚胎的自动分类算法临床验证:囊胚形成、整倍体、着床与活产潜能的预测分析

Clinical validation of an automatic classification algorithm applied on cleavage stage embryos: analysis for blastulation, euploidy, implantation, and live-birth potential.
PubMed 文献 · Hum Reprod · 2023-01-01

该回顾性队列研究在单一IVF诊所2018至2021年间,对卵子捐赠周期(423周期,3736枚胚胎)和自体周期PGT-A(185周期,1291枚胚胎)的胚胎,于第3天用自动胚胎评估算法分为1(最佳)至5(最差)分。算法评分对囊胚形成、着床和活产有显著预测价值,尤其与常规形态学评估联合时;但对整倍体无显著预测价值。

要点

  • 自动算法第3天评分对囊胚形成、着床和活产有显著预测价值,但对整倍体无显著预测价值。
  • 评分1 vs 5的囊胚形成OR=15.849(P<0.001),着床OR=2.920,活产OR=3.317。
  • 算法评分与常规形态学联合预测着床AUC=0.629,预测活产AUC=0.636。

核心结论

  • 自动胚胎评估算法提供的分类对囊胚发育、着床和活产有显著预测价值,尤其与常规形态学评估联合时,但对整倍体无显著预测价值。

研究设计与样本

  • 观察性回顾性队列研究,在单一IVF诊所2018至2021年进行,纳入卵子捐赠周期423个周期共3736枚胚胎和自体周期PGT-A 185个周期共1291枚胚胎。

主要发现

  • 囊胚率随算法评分降低而升高,广义估计方程显示评分1 vs 5的囊胚形成OR=15.849(P<0.001),在卵子捐赠和自体PGT-A胚胎中一致。
  • 评分1 vs 5的着床OR=2.920(95%CI 1.440-5.925;P=0.003;E=2.81),活产OR=3.317(95%CI 1.615-6.814;P=0.001;E=3.04),但在PGT-A胚胎中未发现此关联。
  • 算法评分与常规形态学分类联合时预测性能最高,着床潜能AUC=0.629,活产潜能AUC=0.636。
  • 在PGT-A胚胎中,算法评分与整倍体状态无关联(评分1 vs 5的OR=0.755(95%CI 0.255-0.981);P=0.489;E=1.57)。

关键数值与推荐

  • 算法基于四个参数于第3天将胚胎分为1至5分:P2(t3-t2)、P3(t4-t3)、卵母细胞年龄和细胞数。
  • 共959枚胚胎基于常规形态学评估选择在第5或第6天移植。

临床怎么用

  • 时差成像技术联合自动胚胎评估可与常规形态学评估一起使用,以提高胚胎选择过程的准确性并改善辅助生殖周期的成功率。

局限性

  • 研究的回顾性性质可能是需要谨慎的原因,尽管大样本量加强了模型用于胚胎选择的能力。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is a commercially available embryo assessment algorithm for early embryo evaluation based on the automatic annotation of morphokinetic timings a useful tool for embryo selection in IVF cycles? SUMMARY ANSWER: The classification provided by the algorithm was shown to be significantly predictive, especially when combined with conventional morphological evaluation, for development to blastocyst, implantation, and live birth, but not for euploidy. WHAT IS KNOWN ALREADY: The gold standard for embryo selection is still morphological evaluation conducted by embryologists. Since the introduction of time-lapse technology to embryo culture, many algorithms for embryo selection have been developed based on embryo morphokinetics, providing complementary information to morphological evaluation. However, manual annotations of developmental events and application of algorithms can be time-consuming and subjective processes. The introduction of automation to morphokinetic annotations is a promising approach that can potentially reduce subjectivity in the embryo selection process and improve the workflow in IVF laboratories. STUDY DESIGN, SIZE, DURATION: This observational, retrospective cohort study was performed in a single IVF clinic between 2018 and 2021 and included 3736 embryos from oocyte donation cycles (423 cycles) and 1291 embryos from autologous cycles with preimplantation genetic testing for aneuploidies (PGT-A, 185 cycles). Embryos were classified on Day 3 with a score from 1 (best) to 5 (worst) by the automatic embryo assessment algorithm. The performance of the embryo classification model for blastocyst development, implantation, live birth, and euploidy prediction was assessed. PARTICIPANTS/MATERIALS, SETTING, METHODS: All embryos were monitored by a time-lapse system with an automatic cell-tracking and embryo assessment software during culture. The embryo assessment algorithm was applied on Day 3, resulting in embryo classification from 1 to 5 (from highest to lowest developmental potential) depending on four parameters: P2 (t3-t2), P3 (t4-t3), oocyte age, and number of cells. There were 959 embryos selected for transfer on Day 5 or 6 based on conventional morphological evaluation. The blastocyst development, implantation, live birth, and euploidy rates (for embryos subjected to PGT-A) were compared between the different scores. The correlation of the algorithm scoring with the occurrence of those outcomes was quantified by generalized estimating equations (GEEs). Finally, the performance of the GEE model using the embryo assessment algorithm as the predictor was compared to that using conventional morphological evaluation, as well as to a model using a combination of both classification systems. MAIN RESULTS AND THE ROLE OF CHANCE: The blastocyst rate was higher with lower the scores generated by the embryo assessment algorithm. A GEE model confirmed the positive association between lower embryo score and higher odds of blastulation (odds ratio (OR) (1 vs 5 score) = 15.849; P < 0.001). This association was consistent in both oocyte donation and autologous embryos subjected to PGT-A. The automatic embryo classification results were also statistically associated with implantation and live birth. The OR of Score 1 vs 5 was 2.920 (95% CI 1.440-5.925; P = 0.003; E = 2.81) for implantation and 3.317 (95% CI 1.615-6.814; P = 0.001; E = 3.04) for live birth. However, this association was not found in embryos subjected to PGT-A. The highest performance was achieved when combining the automatic embryo scoring and traditional morphological classification (AUC for implantation potential = 0.629; AUC for live-birth potential = 0.636). Again, no association was found between the embryo classification and euploidy status in embryos subjected to PGT-A (OR (1 vs 5) = 0.755 (95% CI 0.255-0.981); P = 0.489; E = 1.57). LIMITATIONS, REASONS FOR CAUTION: The retrospective nature of this study may be a reason for caution, although the large sample size reinforced the ability of the model for embryo selection. WIDER IMPLICATIONS OF THE FINDINGS: Time-lapse technology with automated embryo assessment can be used together with conventional morphological evaluation to increase the accuracy of embryo selection process and improve the success rates of assisted reproduction cycles. To our knowledge, this is the largest embryo dataset analysed with this embryo assessment algorithm. STUDY FUNDING/COMPETING INTEREST(S): This research was supported by Agencia Valenciana de Innovació and European Social Fund (ACIF/2019/264 and CIBEFP/2021/13). In the last 5 years, M.M. received speaker fees from Vitrolife, Merck, Ferring, Gideon Richter, Angelini, and Theramex, and B.A.-R. received speaker fees from Merck. The remaining authors have no competing interests to declare. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Valera MA, Aparicio-Ruiz B, Pérez-Albalá S, et al. Clinical validation of an automatic classification algorithm applied on cleavage stage embryos: analysis for blastulation, euploidy, implantation, and live-birth potential. Hum Reprod. 2023. PMID: 37018626. doi:10.1093/humrep/dead058

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。